Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Evans Syndrome Companies

ID: MRFR/LS/3700-HCR
85 Pages
Vikita Thakur
Last Updated: February 16, 2025
In the field of autoimmune disorders, Evans Syndrome companies focus on developing targeted therapies and interventions. These organizations aim to improve the understanding and management of Evans Syndrome, contributing to better patient outcomes.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Evans Syndrome Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.89%
2024 Market Size$ 80 Million
2025 Market Size$ 84.71 Million
2035 Market Size$ 150.14 Million
Key Players
Roche
Novartis
Bristol-Myers Squibb
Amgen
GSK
Pfizer
Opportunities
  • Regulatory Support for Orphan Drugs
  • Advancements in Diagnostic Technologies
  • Rising Incidence of Autoimmune Disorders

Top Industry Leaders in the Evans Syndrome Market

Evans Syndrome Market
 

Latest Evans Syndrome Companies Updates:

Apellis Pharmaceuticals: Acquired Tioma Therapeutics, gaining access to their promising complement inhibitor for treating rare blood diseases, including Evans syndrome.

Travere Biopharmaceuticals: Partnered with Akcea Therapeutics to develop and commercialize pegcetacoplan for treating certain blood diseases, including Evans syndrome.

List of Evans Syndrome Key companies in the market:

  • Pfizer, Merck & Co.
  • Sanofi
  • Astellas Pharma, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Enzon Pharmaceuticals, Inc.
  • Bayer AG
  • Sigma-Aldrich
  • Abbott Laboratories
  • Eli Lily and Company
  • BD
  • ChemoMetec A/S